Cargando…

Novel Immune Stimulant Amplifies Direct Tumoricidal Effect of Cancer Ablation Therapies and Their Systemic Antitumor Immune Efficacy

Ablation therapies have emerged as an effective tool for destroying cancerous tissue, but for advanced and disseminated tumors their application remains mainly a palliative measure. However, it is becoming increasingly clear that this limitation can be redressed by the use of intratumoral immune sti...

Descripción completa

Detalles Bibliográficos
Autores principales: Korbelik, Mladen, Hode, Tomas, Lam, Samuel S. K., Chen, Wei R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7996593/
https://www.ncbi.nlm.nih.gov/pubmed/33668932
http://dx.doi.org/10.3390/cells10030492
_version_ 1783670138982105088
author Korbelik, Mladen
Hode, Tomas
Lam, Samuel S. K.
Chen, Wei R.
author_facet Korbelik, Mladen
Hode, Tomas
Lam, Samuel S. K.
Chen, Wei R.
author_sort Korbelik, Mladen
collection PubMed
description Ablation therapies have emerged as an effective tool for destroying cancerous tissue, but for advanced and disseminated tumors their application remains mainly a palliative measure. However, it is becoming increasingly clear that this limitation can be redressed by the use of intratumoral immune stimulating agents for amplifying potential antitumor immune responses that are induced by ablation therapies. A novel immune stimulating drug IP-001, a specific variant of the N-dihydrogalactochitosan (GC) family of molecules, has shown to be effective against metastatic tumors, when combined with different forms tumor ablation. It acts as a multi-function immune stimulant both by directly inhibiting cell membrane repair and recycling of ablation-damaged tumor cells, and indirectly by sequestering ablation-released tumor antigens, as well as recruiting and stimulating antigen presenting cells to induce a potent Th1 type T cell response against the cancer. In this review, we briefly discuss the current applications of local ablation for cancer treatment and the effects of GC in combination with other ablation therapies, a therapeutic approach that is pioneering the field of Interventional Immuno-Oncology (IIO).
format Online
Article
Text
id pubmed-7996593
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79965932021-03-27 Novel Immune Stimulant Amplifies Direct Tumoricidal Effect of Cancer Ablation Therapies and Their Systemic Antitumor Immune Efficacy Korbelik, Mladen Hode, Tomas Lam, Samuel S. K. Chen, Wei R. Cells Review Ablation therapies have emerged as an effective tool for destroying cancerous tissue, but for advanced and disseminated tumors their application remains mainly a palliative measure. However, it is becoming increasingly clear that this limitation can be redressed by the use of intratumoral immune stimulating agents for amplifying potential antitumor immune responses that are induced by ablation therapies. A novel immune stimulating drug IP-001, a specific variant of the N-dihydrogalactochitosan (GC) family of molecules, has shown to be effective against metastatic tumors, when combined with different forms tumor ablation. It acts as a multi-function immune stimulant both by directly inhibiting cell membrane repair and recycling of ablation-damaged tumor cells, and indirectly by sequestering ablation-released tumor antigens, as well as recruiting and stimulating antigen presenting cells to induce a potent Th1 type T cell response against the cancer. In this review, we briefly discuss the current applications of local ablation for cancer treatment and the effects of GC in combination with other ablation therapies, a therapeutic approach that is pioneering the field of Interventional Immuno-Oncology (IIO). MDPI 2021-02-25 /pmc/articles/PMC7996593/ /pubmed/33668932 http://dx.doi.org/10.3390/cells10030492 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ).
spellingShingle Review
Korbelik, Mladen
Hode, Tomas
Lam, Samuel S. K.
Chen, Wei R.
Novel Immune Stimulant Amplifies Direct Tumoricidal Effect of Cancer Ablation Therapies and Their Systemic Antitumor Immune Efficacy
title Novel Immune Stimulant Amplifies Direct Tumoricidal Effect of Cancer Ablation Therapies and Their Systemic Antitumor Immune Efficacy
title_full Novel Immune Stimulant Amplifies Direct Tumoricidal Effect of Cancer Ablation Therapies and Their Systemic Antitumor Immune Efficacy
title_fullStr Novel Immune Stimulant Amplifies Direct Tumoricidal Effect of Cancer Ablation Therapies and Their Systemic Antitumor Immune Efficacy
title_full_unstemmed Novel Immune Stimulant Amplifies Direct Tumoricidal Effect of Cancer Ablation Therapies and Their Systemic Antitumor Immune Efficacy
title_short Novel Immune Stimulant Amplifies Direct Tumoricidal Effect of Cancer Ablation Therapies and Their Systemic Antitumor Immune Efficacy
title_sort novel immune stimulant amplifies direct tumoricidal effect of cancer ablation therapies and their systemic antitumor immune efficacy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7996593/
https://www.ncbi.nlm.nih.gov/pubmed/33668932
http://dx.doi.org/10.3390/cells10030492
work_keys_str_mv AT korbelikmladen novelimmunestimulantamplifiesdirecttumoricidaleffectofcancerablationtherapiesandtheirsystemicantitumorimmuneefficacy
AT hodetomas novelimmunestimulantamplifiesdirecttumoricidaleffectofcancerablationtherapiesandtheirsystemicantitumorimmuneefficacy
AT lamsamuelsk novelimmunestimulantamplifiesdirecttumoricidaleffectofcancerablationtherapiesandtheirsystemicantitumorimmuneefficacy
AT chenweir novelimmunestimulantamplifiesdirecttumoricidaleffectofcancerablationtherapiesandtheirsystemicantitumorimmuneefficacy